Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel.Karim Fizazi, Robert Dreicer, Fred Saad et al.|Journal of Clinical Oncology|2014Cited by 3
Circulating tumor cells (CTCs) and LDH as prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial.Howard I. Scher, Robert Dreicer, Karim Fizazi et al.|Journal of Clinical Oncology|2014Cited by 1